GlassScriptPhysician profile
Eric Mckee Kiskaddon
NPI 1366838815
$4,156.00
in general payments reported to CMS, 2019-2025
15 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.56 · 2020: $63.45 · 2022: $2,785 · 2023: $512 · 2024: $489 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $2,419.05 | 2022 | |
| Stryker Corporation | $874.67 | 2022-2024 | Mako, Triathlon |
| Heron Therapeutics, INC. | $205.00 | 2022-2024 | Zynrelef |
| Inari Medical, INC. | $189.06 | 2022 | |
| Davol INC. | $131.74 | 2025 | Surgiphor |
| Mallinckrodt Hospital Products INC. | $63.45 | 2020 | |
| Becton, Dickinson and Company | $55.38 | 2022-2024 | Arista Ah Flexitip |
| Avanos Medical | $48.56 | 2019 | |
| Ferring Pharmaceuticals INC. | $46.64 | 2025 | Euflexxa |
| Acumed LLC | $29.52 | 2024 | Acumed |
| Bioventus LLC | $29.09 | 2025 | Durolane |
| Ethicon US, LLC | $19.51 | 2025 | Vistaseal |
| Vertex Pharmaceuticals Incorporated | $17.17 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $13.67 | 2025 | Zilretta, Iovera |
| Aroa Biosurgery Incorporated | $13.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Kiskaddon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.